ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 408,64
-0,30%
Dow Jones
42 297,12
0,86%
DAX
20 132,85
-0,44%
Brent Oil
79,865
-0,52%
Bitcoin
95 065,14
0,59%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Cyclerion Therapeutics Inc (CYCN) Cours

Cyclerion Therapeutics Inc

Cyclerion Therapeutics Inc (CYCN)

NASDAQ
3,23
-0,06
(-1,82%)
Fermé 14 Janvier 10:00PM
Retardé de 15 minutes
3,21
-0,02
(-0,62%)
Après les heures de négociation: 1:59AM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
3,23
Prix Achat
2,92
Prix Vente
3,41
Volume échangé
55 443
3,06 Fourchette du Jour 3,40
1,27 Plage de 52 semaines 9,4699
Cap du marché
8,754M
Clôture Veille
3,29
Ouverture
3,40
Dernière Transaction
5
@
3.41
Dernière heure de transaction
Volume financier
US$ 178 432
VWAP
3,2183
Volume moyen (3 m)
3 446 938
Actions en circulation
2 710 096
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-1,65
Bénéfice par action (BPA)
-1,94
Chiffre d'affairess
-
Bénéfice net
-5,26M

À propos de Cyclerion Therapeutics Inc

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of nex... Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.cyclerion.com
Siège social
Boston, Massachusetts, USA
Fondé
-
Cyclerion Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker CYCN. Le dernier cours de clôture d'Cyclerion Therapeutics était de US$3,29. Au cours de la dernière année, les actions de Cyclerion Therapeutics ont été négociées dans une fourchette de prix de US$ 1,27 à US$ 9,4699.

Cyclerion Therapeutics compte actuellement 2 710 096 actions en circulation. La capitalisation boursière d'Cyclerion Therapeutics est de US$8,92 million. Cyclerion Therapeutics a un ratio cours/bénéfice (ratio PE) de -1.65.

CYCN Dernières nouvelles

Plus de nouvelles

Form 8-K - Current report

17 Décembre 2024
Edgar (US Regulatory)

Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The...

17 Décembre 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

14 Novembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 Août 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 Août 2024
Edgar (US Regulatory)

Regina Graul, Ph.D., Promoted to Chief Executive Officer

CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer...

07 Août 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Août 2024
Edgar (US Regulatory)

Form 8-K - Current report

14 Juin 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Mai 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

26 Janvier 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.08-2.4169184293.313.46553.0528679173.20193648CS
4-0.03-0.9202453987733.263.792.81400843.1435234CS
120.7429.7188755022.499.46991.2734469385.2912912CS
26-0.12-3.582089552243.359.46991.2715624985.28632094CS
52-0.51-13.63636363643.749.46991.277924085.28114907CS
156-25.37-88.706293706328.629.81.273589667.37367854CS
260-66.97-95.398860398970.2179.21.2744331341.95986249CS

CYCN - Frequently Asked Questions (FAQ)

What is the current Cyclerion Therapeutics share price?
The current share price of Cyclerion Therapeutics is US$ 3,23
How many Cyclerion Therapeutics shares are in issue?
Cyclerion Therapeutics has 2 710 096 shares in issue
What is the market cap of Cyclerion Therapeutics?
The market capitalisation of Cyclerion Therapeutics is USD 8,92M
What is the 1 year trading range for Cyclerion Therapeutics share price?
Cyclerion Therapeutics has traded in the range of US$ 1,27 to US$ 9,4699 during the past year
What is the PE ratio of Cyclerion Therapeutics?
The price to earnings ratio of Cyclerion Therapeutics is -1,65
What is the reporting currency for Cyclerion Therapeutics?
Cyclerion Therapeutics reports financial results in USD
What is the latest annual profit for Cyclerion Therapeutics?
The latest annual profit of Cyclerion Therapeutics is USD -5,26M
What is the registered address of Cyclerion Therapeutics?
The registered address for Cyclerion Therapeutics is 155 FEDERAL STREET, SUITE 700, BOSTON, MASSACHUSETTS, 02110
What is the Cyclerion Therapeutics website address?
The website address for Cyclerion Therapeutics is www.cyclerion.com
Which industry sector does Cyclerion Therapeutics operate in?
Cyclerion Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
PHIOPhio Pharmaceuticals Corporation
US$ 6,50
(284,62%)
281,98M
SLRXSalarius Pharmaceuticals Inc
US$ 3,65
(133,23%)
120,26M
VRMEVerifyMe Inc
US$ 4,1575
(63,04%)
57,6M
ATPCAgape ATP Corporation
US$ 1,9645
(55,91%)
84,16M
AVGRAvinger Inc
US$ 0,8248
(46,47%)
9,78M
EHGOEshallgo Inc
US$ 1,2408
(-62,06%)
6,74M
CMTLComtech Telecommunications Corporation
US$ 2,3491
(-43,12%)
4,37M
SVMHSRIVARU Holding Ltd
US$ 0,0352
(-43,04%)
184,27M
LAESSEALSQ Corporation
US$ 3,35
(-41,54%)
89,92M
NMHINatures Miracle Holding Inc
US$ 1,12
(-38,80%)
735,08k
GCTKGlucoTrack Inc
US$ 0,1493
(27,61%)
685,02M
PHIOPhio Pharmaceuticals Corporation
US$ 6,50
(284,62%)
281,98M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0627
(-28,83%)
232,25M
NVDANVIDIA Corporation
US$ 133,23
(-1,97%)
204,68M
RGTIRigetti Computing Inc
US$ 6,0344
(-32,43%)
192,21M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
CYCN
Cyclerion Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés